Literature DB >> 8107951

Charge distribution of IgA-lambda in IgA nephropathy.

K N Lai1, S H Chui, W H Lewis, A S Poon, C W Lam.   

Abstract

The finding that eluted mesangial IgA and serum IgA from patients with IgA nephropathy had a restricted anionic charge contrasting with normal serum IgA prompted us to study the charge of the kappa and lambda subclasses of IgA. Serum IgA from 11 patients with IgA nephropathy and 11 controls was purified by affinity chromatography by binding to jacalin. The charges of IgA were studied by a novel method. The spectrotype of total IgA was first studied by isoelectric focusing and immunoblotting. IgA lambda and IgA kappa was further analyzed by reacting with specific monoclonal antibodies. The amount of IgA with different pIs was analyzed by computerized densitometry. The anionic:cationic (A:C) ratio of IgA using pI 5.6 as the dividing point was greater in patients (at clinical quiescence and during exacerbation) than in controls (1.67 +/- 0.31 versus 1.36 +/- 0.27, p < 0.025). IgA lambda in both groups was anionic (A:C ratio 2.22 +/- 0.77 versus 2.36 +/- 0.36) and IgA kappa was cationic (A:C ratio 1.15 +/- 0.36 versus 1.04 +/- 0.39) but no difference in the A:C ratio was demonstrated. The increased A:C ratio in total IgA in patients was due to raised serum IgA lambda (kappa/lambda ratio 1.11 +/- 0.14 in patients and 1.51 +/- 0.16 in controls, p < 0.01). We had previously shown a predominant mesangial deposition of IgA lambda in IgA nephropathy. Animal experiments have revealed the preferential mesangial deposition of immune complexes is related to their anionic charges. Our data of raised anionic IgA lambda in IgA nephropathy may be important in determining its selective mesangial binding that could contribute to the immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107951     DOI: 10.1159/000187763

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

2.  Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy.

Authors:  Joseph C K Leung; Sydney C W Tang; Daniel T M Chan; Sing Leung Lui; Kar Neng Lai
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

3.  IgA Structure Variations Associate with Immune Stimulations and IgA Mesangial Deposition.

Authors:  Zeliha Oruc; Christelle Oblet; Ahmed Boumediene; Anne Druilhe; Virginie Pascal; Elisabeth Le Rumeur; Armelle Cuvillier; Chahrazed El Hamel; Sandrine Lecardeur; Tomas Leanderson; Willy Morelle; Jocelyne Demengeot; Jean-Claude Aldigier; Michel Cogné
Journal:  J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 10.121

4.  Clinicopathologic and Prognostic Study of Primary IgA Nephropathy With Light Chain λ Restriction in the Mesangial Deposits.

Authors:  Ji Zhang; Ziyuan Huang; Sishi Lin; Ya Hu; Yan Liang; Wenxian Qiu; Bo Chen; Chaosheng Chen
Journal:  Kidney Int Rep       Date:  2022-01-26

5.  Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.

Authors:  Katerina Zachova; Jana Jemelkova; Petr Kosztyu; Yukako Ohyama; Kazuo Takahashi; Josef Zadrazil; Jiri Orsag; Karel Matousovic; Dana Galuszkova; Nadezda Petejova; Jiri Mestecky; Milan Raska
Journal:  J Am Soc Nephrol       Date:  2022-02-03       Impact factor: 14.978

6.  Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.

Authors:  Kazuo Takahashi; Milan Raska; Milada Stuchlova Horynova; Stacy D Hall; Knud Poulsen; Mogens Kilian; Yoshiyuki Hiki; Yukio Yuzawa; Zina Moldoveanu; Bruce A Julian; Matthew B Renfrow; Jan Novak
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.